Hence, immunotherapeutics that augment CD8 T-cell anti-tumor activity - such as anti-PD1 and anti-CTLA4 mAbs - given in combination with trastuzumab in patients with HER2+ BC may improve outcome by involving and enhancing critical host immunity [41,48,49]. The gene discussed is CTLA4; the disease is neoplasm.